Metis TechBio Co., Ltd.

剂泰科技(北京)股份有限公司

07666.HK

Develops AI-driven nanomaterial delivery technologies, including a proprietary lipid library and AI platforms, to design lipid nanoparticles for drug delivery, serving pharmaceutical development of innovative medicines, with expansion into longevity and animal health.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Outsourced production (OEM / contract manufacturing)
• Overseas markets and operations
• Losses and path to profitability
• Negative operating cash flow
• Cash burn and runway
• Goodwill, intangibles and asset impairment
• Preferred shares and fair-value liabilities
• Investments and fair-value assets
• Non-IFRS measures and adjustments
• Material share-based payments
• Chapter 18C specialist technology